Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Peripheral Nervous System Diseases 5Lymphoma 5Breast Neoplasms 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Stomatitis 2Stomach Neoplasms 2Sarcoma 2Pain 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Malnutrition 2Wilms Tumor 1Vaso-Occlusive Crises 1Squamous Cell Carcinoma of Head and Neck 1Sarcopenia 1Recurrence 1Radiation Injuries 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Oral Complications 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Malignant mesenchymal tumor 1

Interventions

Dexamethasone 110Cyclophosphamide 99Melphalan 91Bortezomib 68Peripheral Blood Stem Cell Transplantation 63Lenalidomide 57fludarabine phosphate 55Busulfan 53Filgrastim 50Antilymphocyte Serum 38Tacrolimus 37Thalidomide 36Radiotherapy 36Mycophenolic Acid 32fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Prednisone 21Whole-Body Irradiation 20Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 14Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Plasma Cell × Glutamine × Clear all
NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡